|
Standalone |
|
Aurobindo Pharma Limited, for the year ended 31
March 2006, has registered a total income of
Rs.15,026 million (Rs.11,757 million) and a net
profit of Rs. 694 million (Rs.351 million).
Profit after tax and total income have grown by
98% and 28% respectively. |
|
Consolidated |
|
On a consolidated
basis, the total income stands at Rs.17,577
million (Rs. 14,218 million). The net profit
after adjustments stands at Rs. 697 million (Rs.
32.5 million) and has grown multifold. |
|
Quarter |
|
For the quarter
ended 31st March 2006, the company has
registered a landmark total income of Rs. 4,742
million (Rs.2,931 million) registering an
impressive growth of 62%. The Profit after tax
surged by multifold to Rs. 375 million (Rs.39
million). |
|
EBIDTA |
|
EBIDTA for Q4 increased to 17.46% and has grown
by 364%. EBIDTA, on standalone and consolidated
basis for the year ended stands at Rs.2,046
million (Rs.1234 million) and Rs.2,398 million
(Rs.1,313 million) respectively. EBIDTA has
grown by 66% and 83% respectively for stand
alone and consolidated levels. |
|
Exports |
|
For the Q4, the exports stand at Rs. 3,176
million (Rs.1,690 million) registering a growth
of 88%. Exports in Q4 constitute 69% of total
sales, which is another landmark for Aurobindo.
For the year ended, the exports stand at
Rs.8,605 million (Rs.5,758 million) registering
a growth of 49% and constitute 58% of the total
sales. |
|
Formulations |
|
The formulations
sales for the quarter stand at Rs.1,068 million
(Rs.289 million). The formulation business
contributes to 23% (10%) of sales reflecting the
rapid momentum in the formulations business. |
|
Financial snapshot |
| |
Q4 |
% Growth |
Standalone |
% Growth |
Consolidated |
% Growth |
|
Total Income |
4742 |
62% |
15026 |
28% |
17577 |
24% |
|
Exports |
3176 |
88% |
8605 |
49% |
|
|
|
EBIDTA |
828 |
365% |
2046 |
66% |
2398 |
93% |
|
EBIDTA % |
17.5 |
|
13.6 |
|
13.6 |
|
|
PAT |
375 |
862% |
694 |
98% |
711 |
1833% |
|
|
Regulated market initiatives (record facility
approvals, DMFs / ANDA’s filings) on an
accelerated basis helped Aurobindo in achieving
the transition successfully. |
|
Year 2005 - 06 was a
very eventful and successful year for Aurobindo
Pharma. The leadership of Aurobindo in
chemistry, technology and project execution in
generic pharmaceutical industry is visible
during the year with several patents, DMFs /
ANDAs and plant approvals by various agencies.
The company has achieved the transition from an
API company in semi regulated markets to a
vertically integrated pharma company in both
regulated and semi regulated markets, with
comprehensive capabilities in IPR generation,
formulation & chemical research; formulation &
API production to penetrate global markets.
Aurobindo strongly believes that Vertical
integration in IPR, intermediates, APIs and
formulations is key for sustainable long-term
profit in global pharmaceutical industry.
Aurobindo has been pursuing aggressive filings
of API DMFs and formulation dossiers in US, EU,
Canada, and other key markets to emerge as a
significant provider of pharmaceuticals. |
|
75 Patents |
|
During the year, 75
patents are filed for API/formulation processes
taking the total cumulative patents filed to
180. Entry into regulated markets often requires
innovative processes that are not infringing.
Such a robust back up of intellectual property
helps Aurobindo Pharma in penetrating to key
regulated markets. |
|
38 Drug Master filings for
the USA market |
|
During the year, 38
DMFs have been filed, taking the cumulative
filings to 67 in the US. The cumulative filings
of DMFs in key markets stand at 142. This takes
the global filings to a cumulative figure of
278. This is a very significant leap and an
acknowledged achievement in the pharmaceutical
industry. |
|
32 ANDAs for the USA market |
|
During the year, 32
ANDAs were filed, taking the cumulative filings
to 51 for the US. 89 filings have been done in
key regulated markets including US and Europe
taking the total cumulative filings in regulated
markets to 123. Global filings stand at 537
ANDAs. Such a significant number of filings in a
single year are a rare phenomenon in the
pharmaceutical world. |
|
Aggressive filings for the
USA market |
| |
During the year |
Cumulative |
|
ANDAs |
32 |
51 |
|
DMFs |
38 |
67 |
|
Approvals
(including Tentative) |
22 |
25 |
|
|
Product
approvals and facility approvals |
|
Aurobindo has
received 22 approvals (including tentative
approvals) for USA. Product approvals in UK and
in Canada have also begun.
Several key
facilities are approved by USFDA, UK MHRA,
Health Canada, MCC (South Africa), Brazil (Anvisa),
(see Annexure I) |
|
Europe |
|
During the year, the
company has acquired Milpharm Limited in UK, a
generic formulation company with over 100
approved marketing authorizations. This is
Aurobindo’s first acquisition in Europe. The
company has started receiving approvals for its
formulations and APIs for the European market.
|
|
ARVs |
|
The company has
received several approvals for its range of
ARV’s during the year. The company has the
largest number of products approved by US FDA
under PEPFAR programme.
Aurobindo has many
firsts to its credit. It has received Efavirenz,
Abacavir, Lamivudine and zidovudine combination
as first generic approval. The company has
Lamivudine and zidovudine as fixed dose Tablets
co-packed with Efavirenz as also a first NDA.
Besides, Company’ has received approval for
Stavudine tablets, Nevirapine tablets and
solution, Zidovudine oral solution. |
|
Accolades |
|
1. Aurobindo has received “THE BEST BULK
DRUG COMPANY” FOR THE YEAR 2004-05 given by
Pharma Express. |
|
2. The company has also won “THE PATENT
APPRECIATION AWARD” by the Indian Drug
Manufacturers’. |
|
3. The company has received “Best
Management Award” for the year 2005 from Andhra
Pradesh Government. |
|
|
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma
Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company’s robust
product portfolio is spread over 6 major
therapeutic/product areas encompassing
(Antibiotics, Anti-Retrovirals, CVS/Statins/Diabetology,
CNS, Gastro/Uro/Kidney therapeutics, Anti
fungal/allergics/respiratory) around 65
Betalactam APIs and 123 Non-Betalactam APIs. The
Company markets its products in over 100
countries. The company has filed over 51 ANDAs
and 67 DMFs for the USA market, in addition to
several filings in other countries. The company
has received approvals for several facilities
from leading regulatory agencies like US FDA, UK
MHRA, WHO, Health Canada, MCC South Africa. |
|
Annexure I |
|
Aurobindo’s
facility approvals by accredited regulatory
authorities |
|
Unit |
Certifications |
|
API |
|
Unit I |
US FDA |
|
Unit 1 A |
US FDA |
|
Unit VI A |
Health Canada, US FDA
(pre approval over) |
|
Unit VIII |
US FDA, WHO |
|
Unit XI |
US FDA |
|
Formulations |
|
Unit III |
US FDA, UK MHRA,
WHO, Health Canada, MCC (SA), Brazil Anvisa
|
|
Unit VI B |
US FDA, MCC (SA), Health
Canada, Brazil Anvisa |
|
Unit XII |
US FDA, Health
Canada, UK MHRA, Brazil Anvisa
|
|
|
|
PRESS
ROOM
